Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Pittsburgh Monash University |
---|---|
Information provided by: | University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT00177723 |
The study will evaluate and improve the performance of pharmaco-statistical models previously developed in the compassionate use program in patients being treated with linezolid under clinical usage conditions. This study will also develop a sensitive and specific tool that may be used to predict patients at risk of hematological toxicity, based on factors including linezolid concentration and duration of therapy and use these models to better understand the determinants of toxicity with linezolid and define better strategies to manage toxicity or reduce its occurrence.
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Towards Reducing Resistance and Hematological Toxicity of Linezolid |
Estimated Enrollment: | 50 |
Study Start Date: | August 2005 |
Study Completion Date: | February 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
University of Pittsburgh Medical Center | |
Pittsburgh, Pennsylvania, United States, 15213 |
Principal Investigator: | David L Paterson, MD | University of Pittsburgh |
Study ID Numbers: | IRB# 0501019 |
Study First Received: | September 13, 2005 |
Last Updated: | December 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00177723 |
Health Authority: | United States: Institutional Review Board; Australia: National Health and Medical Research Council |
receiving antibiotic Linezolid clinically |
Linezolid |
Protein Synthesis Inhibitors Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Enzyme Inhibitors Infection Pharmacologic Actions |